Table 1. Characteristics of patients with early-stage NSCLC stratified according to treatment.
| Variable | Overall cohort, n (%) | SBRT, n (%) | Sublobar resection, n (%) | P |
|---|---|---|---|---|
| Sociodemographics | ||||
| Age (years) | <0.001 | |||
| <65 | 110 (48) | 19 (17) | 91 (75) | |
| 65–74 | 61 (27) | 34 (31) | 27 (22) | |
| ≥75 | 59 (26) | 56 (51) | 3 (2) | |
| Gender | 0.004 | |||
| Male | 144 (63) | 79 (73) | 65 (54) | |
| Female | 86 (37) | 30 (27) | 56 (46) | |
| FEV1 (L) | <0.001 | |||
| <1.0 | 28 (12) | 26 (24) | 2 (2) | |
| ≥1.0, <2.0 | 97 (42) | 57 (52) | 40 (33) | |
| ≥2.0 | 105 (46) | 26 (24) | 79 (65) | |
| FEV1/FVC (%) | <0.001 | |||
| ≥70 | 211 (92) | 91 (83) | 120 (99) | |
| <70 | 19 (8) | 18 (17) | 1 (1) | |
| DLCO% predicted | 0.513 | |||
| <60 | 56 (24) | 32 (29) | 24 (20) | |
| 60–79 | 49 (21) | 26 (24) | 23 (19) | |
| ≥80 | 125 (54) | 51 (47) | 74 (61) | |
| KPS | 0.597 | |||
| ≥90 | 201 (87) | 89 (82) | 112 (93) | |
| <90 | 29 (13) | 20 (18) | 9 (7) | |
| CCI | <0.001 | |||
| 0 | 126 (55) | 42 (39) | 84 (69) | |
| 1–2 | 91 (40) | 58 (53) | 33 (27) | |
| ≥3 | 13 (5) | 9 (8) | 4 (4) | |
| Tumor characteristics | ||||
| Tumor size (7) | <0.001 | |||
| ≤2.0 | 147 (64) | 56 (51) | 91 (75) | |
| 2.1–3.0 | 64 (28) | 41 (38) | 23 (19) | |
| 3.1–5.0 | 19 (8) | 12 (11) | 7 (6) | |
| Histology | <0.001 | |||
| NSCLC-NOS | 18 (8) | 15 (14) | 3 (2) | |
| Adenocarcinoma | 157 (68) | 53 (48) | 104 (86) | |
| Squamous | 40 (17) | 26 (24) | 14 (12) | |
| Probable | 15 (7) | 15 (14) | 0 (0) |
SBRT, stereotactic body radiotherapy; NOS, not otherwise specified; NSCLC, non-small cell lung cancer; Ade, adenocarcinoma; SCC, squamous cell carcinoma; FEV1, forced expiratory volume in 1 second; FEV1/FVC%, FEV1 and forced vital capacity ratio; DLCO, carbon monoxide diffusing capacity; CCI, Charlson comorbidity index; KPS, Karnofsky performance status.